Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era

By sjmartinez • March 26, 2023

Ma TM, Feng FY, Rosenthal SA, Rettig MB, Raldow AC, Spratt DE, Xiang M, Kishan AU. Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era. Prostate Cancer Prostatic Dis. 2023 Mar 25. doi: 10.1038/s41391-023-00663-5. Epub ahead of print. PMID: 36966268.

Tags: Hematology/Oncology, Publications, Veterans Administration

Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study

Wang R, Wang S, Mi Y, Huang T, Wang J, Ni J, Wang J, Yin J, Li M, Ran X, Fan S, Sun Q, Tan[...]

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies

Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, Zhu E, Tian Y, Huang J, Rezek V, Kitchen S, Hsiai T, Zhou[...]

Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan[...]